Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...
CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...
David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population. In an interview with ...
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
4d
MedPage Today on MSNDe-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBCUse of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
The US Food and Drug Administration has approved tislelizumab (Tevimbra, BeiGene), in combination with platinum-containing ...
resectable NSCLC patients with PD-L1 expression ≥1% and at high risk of recurrence may be eligible for treatment with Bristol Myers Squibb’s OPDIVO® (nivolumab) in combination with platinum ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results